JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

Search

Sarepta Therapeutics Inc

Closed

SectorHealthcare

11.9 -8.04

Overview

Share price change

24h

Current

Min

11.8

Max

11.99

Key metrics

By Trading Economics

Income

-607M

-448M

Sales

86M

745M

P/E

Sector Avg

27.205

38.156

Profit margin

-60.08

Employees

1,372

EBITDA

-560M

-369M

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

+76.03% upside

Dividends

By Dow Jones

Next Earnings

6 Aug 2025

Market Stats

By TradingEconomics

Market Cap

-9.1B

1.3B

Previous open

19.94

Previous close

11.9

News Sentiment

By Acuity

50%

50%

145 / 375 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Sarepta Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

21 Jul 2025, 11:31 UTC

Major Market Movers

Sarepta Stock Continues to Fall After Patient Death Linked to Investigational Gene Therapy

31 Mar 2025, 14:19 UTC

Major Market Movers

Vaccine Stocks Fall After Ousting of FDA's Vaccine Head

21 Jul 2025, 12:53 UTC

Earnings

These Stocks Are Moving the Most Today: Sarepta, Verizon, Block, Tesla, Domino's, Cleveland-Cliffs, Pinterest, and More -- Barrons.com

21 Jul 2025, 11:17 UTC

Earnings

These Stocks Are Moving the Most Today: Sarepta, Verizon, Block, Tesla, Domino's, Cleveland-Cliffs, and More -- Barrons.com

21 Jul 2025, 10:25 UTC

Earnings

These Stocks Are Moving the Most Today: Sarepta, Block, Tesla, Domino's, Cleveland-Cliffs, Verizon, and More -- Barrons.com

21 Jul 2025, 09:50 UTC

Earnings

These Stocks Are Moving the Most Today: Sarepta, Block, Tesla, Verizon, and More -- Barrons.com

21 Jul 2025, 09:12 UTC

Earnings

These Stocks Are Moving the Most Today: Sarepta, Block, Tesla, Verizon, and More -- Barrons.com

17 Jul 2025, 16:44 UTC

Earnings

These Stocks Are Moving the Most Today: Lucid, TSMC, Elevance, Sarepta, PepsiCo, Abbott Labs, Archer Daniels, and More -- Barrons.com

17 Jul 2025, 13:48 UTC

Earnings

These Stocks Are Moving the Most Today: Lucid, TSMC, United, Sarepta, PepsiCo, Abbott Labs, MP Materials, Archer Daniels, and More -- Barrons.com

17 Jul 2025, 10:57 UTC

Earnings

These Stocks Are Moving the Most Today: TSMC, United Airlines, Sarepta, PepsiCo, GE Aerospace, MP Materials, Archer Daniels, and More -- Barrons.com

17 Jul 2025, 09:08 UTC

Hot Stocks

Stocks to Watch Thursday: TSMC, United Airlines, Sarepta -- WSJ

17 Jun 2025, 09:10 UTC

Hot Stocks

Stocks to Watch Tuesday: SunRun, Enphase Energy, Mitsubishi, Roku -- WSJ

17 Jun 2025, 08:59 UTC

Hot Stocks

Stocks to Watch Tuesday: Sunrun, Enphase Energy, Mitsubishi, Roku -- WSJ

16 Jun 2025, 08:55 UTC

Hot Stocks

Stocks to Watch: Victoria's Secret, Renault, U.S. Steel, Sarepta -- WSJ

Peer Comparison

Price change

Sarepta Therapeutics Inc Forecast

Price Target

By TipRanks

76.03% upside

12 Months Forecast

Average 21 USD  76.03%

High 80 USD

Low 7 USD

Based on 28 Wall Street analysts offering 12 month price targets forSarepta Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

28 ratings

4

Buy

18

Hold

6

Sell

Technical Score

By Trading Central

N/A / 62.47Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Bearish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

145 / 375 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Sarepta Therapeutics Inc

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.